Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
JCI accreditation is recognized globally
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Subscribe To Our Newsletter & Stay Updated